



HIGH PROBABILITY RESULT

Ariosa Diagnostics, Inc. 5945 Optical Court San Jose, CA 95138

Contact Line 1^ Contact Line 2^ Contact Line 3^ Contact Line 5^ Contact Line 6^ Contact Line 7^ Contact Line 8^

Patient and Provider Information PATIENT NAME: Jane Doe DATE OF BIRTH: (MM/DD/YYYY) 01/01/1980 MRN: 1234567890123456789 LABORATORY ID: OTHER ID: AD12345678-PAT GESTATIONAL AGE 10 wks 5 days # OF FETUSES: IVF STATUS: non-IVF pregnancy COLLECTION DATE (MM/DD/YYYY) : RECEIVED DATE (MM/DD/YYYY): 07/20/2015 07/21/2015

ACCOUNT #:

7654321

CLINIC NAME:
The Clinic Offering Test

REFERRING/ORDERING CLINICIAN:
Ordering Physician MD

REFERRING/ORDERING CLINICIAN FAX #:
123-456-7890

OTHER CLINICIAN:
Genetic Counselor MA, CGC

OTHER CLINICIAN FAX #:
987-654-3210

REPORT DATE:
(MM/DD/YYYY)
07/28/2015

st		

Fetal cfDNA Percentage: 10.5%

CHROMOSOME RESULT		PROBABILITY	RECOMMENDATION	
Trisomy 21 (T21)	High Probability	Greater than 99/100 (99%)	Genetic counseling and additional testing	
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient	
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient	

TEST DESCRIPTION

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

CLINICAL DATA

	Detection Rate	False Positive Rate
T21	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
T18	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
T13	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (13%).

Because these conditions are rare, limited numbers of aneuploidy twin and egg donor pregnancies have been evaluated. The negative predictive value for frismy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: http://www.harmonytest.com/PPV

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthrace provider, who can recommend confirmation, diagnostic testing where appropriate where appropriate providers are considered in the providers of the provid